Cell Product Description
Cell to Cure develops ready-to-use, allogeneic adipose tissue-derived mesenchymal stromal/stem cells that help repair and regenerate tissue.
Stromal cells derived from adipose tissue
Cell to Cure develops cell-based therapies using allogeneic adipose tissue-derived mesenchymal stromal/stem cells (ASCs) for cellular therapies.
The ASC products are classified as Advanced Therapy Investigational Medicinal Products (ATIMPs), obtained through isolation and manufacturing processes using adipose tissue sourced from rigorously screened healthy donors. These cells are processed under stringent quality-controlled conditions to ensure consistency, safety, and efficacy in compliance with regulatory standards.
Once manufactured, the ASC products are cryopreserved and stored as ready-to-use “off-the-shelf” cell-based therapies. These products require only a brief thawing period of 5–10 minutes prior to administration, significantly facilitating their clinical application. Such short preparation time enhances their practicality and convenience in clinical settings.
Due to their ease of storage and rapid availability, ASC products can be efficiently distributed to healthcare providers and are suitable for prompt treatment of a wide range of patients. Their standardised formulation and biological properties make them a promising therapeutic tool in regenerative medicine and various immunomodulatory, and inflammation-related applications.
Proven Safety in Clinical Trials
Our cell products have proven safety in more than 300 patients in several phase I and II clinical trials for treatment of conditions such as autism and leaky gut syndrome in children, non-ischemic heart failure, diabetic foot ulcer, complications following lung transplantation, reduced tear production in Sjögren’s syndrome and radiation-induced dry mouth in head and neck cancer patients.
